From a productivity standpoint, group core operating income was up 5%, again driven by IM, which was up 7%. We also had continued our margin progression with a one percentage point improvement. Our savings from our SG&A program are on track and Harry will cover that in a bit more detail. From an innovation standpoint, we had some important events, particularly the approval of Pluvicto with a positive opinion in Europe from the CHMP.